Bioenhanced curcumin may induce remission in ulcerative colitis

Reuters Health - 21/10/2020 - A new curcumin formulation designed to improve oral bioavailability induces remission in patients with mild-to-moderate ulcerative colitis on maximal doses of mesalamine, according to results from a pilot study. Curcumin is said to have immunoregulatory properties, to reduce oxidative stress, to promote mucosal healing, to protect the intestinal barrier, and to inhibit autophagy and antifibrotic actions, but poor oral bioavailability has limited its clinical application. Dr. Rupa Banerjee of Asian Institute of Gastroenterology, in Hyderabad, India, and colleagues examined the efficacy of a bioenhanced version of curcumin (Valdone from Cadila Pharmaceuticals Ltd., in India) in inducing clinical remission in their randomized, double-blind, placebo-controlled study of 69 patients with mild-to-moderate active disease who had been taking maximal doses of oral and rectal mesalamine for at least four weeks. During the three-month study,...

Please login to read the full text of the article.

If you have no account yet, please register now.

Posted on 21 October, 202028 October, 2020